Latest Conference Articles

Investigators present data from the CREDENCE trial during AHA.

Taking a routine invasive approach had no impact on clinical outcomes or quality of life in patients with chronic kidney disease as well as stable ischemic heart disease.

Results of the ISCHEMIA trial were revealed at AHA 2019 and revealed little overall benefit of an invasive approach but saw improved angina control in patients with previous angina.

Apabetalone demonstrated tolerability and safety in the phase 3 BETonMACE trial but the study did not meet its primary end point of reduction in major adverse cardiovascular events (MACE).

The ORION-10 trial revealed 300 mg inclisiran twice-yearly reduced LDL-C levels by 58% in patients with atherosclerotic cardiovascular disease.

In a presentation during AHA, investigators present new evidence linking sleep issues with poorer outcomes for hypertension patients.

New empagliflozin data assesses the SGLT-2 inhibitor versus GLP-1 agonists and DPP-4 inhibitors for patients with heart failure.

Results of the COLCOT trial presented at AHA 2019 revealed colchicine use could reduce the risk of cardiovascular events by 35% in patients who recently suffered a myocardial infarction.

The adult heart failure study is the first of its kind: a completely decentralized, indication-seeking clinical trial.

Studies are ongoing to test the safety and efficacy of treating primary hyperoxaluria type 1 patients with lumasiran.

George Mulligan, PhD, discusses during Kidney Week the results of a phase IIa study showing potential in a new drug to treat patients at risk for developing an acute kidney injury following cardiovascular surgery.

George Bakris, MD, discusses how nephrologists can work with other specialists and what the highlight of Kidney Week was.

For what other indications, and in what regimens, are investigators assessing the drug class?

Todd Alexander, MD, discusses a relatively new field of nephrology research during Kidney Week.

George Bakris, MD, discusses the major study during Kidney Week, as well as what diseases should get more attention in future research.

Certain diet-based comorbid conditions are more prevalent in food-allergic patients.

At least 1 major food allergy trial in recent years has given allergists incentive to set detailed strategies for their patients.

Could the drug class best serve patients as an adjunctive, a monotherapy, or maybe a prophylaxis for symptoms?

During Kidney Week, Katherine Tuttle, MD, discusses the plethora of options available to nephrologists, including dulaglutide.

In a study presented at Kidney Week, investigators breakdown data on the end-of-life care for non-dialysis veterans with chronic kidney disease.

Matthew Weir, MD talks about some of the challenges in nephrology and what has people buzzing while at Kidney Week.

Matthew Weir, MD, discusses the START-CKD trial at Kidney Week.

In an abstract presented at Kidney Week, investigators discuss the differences in treatments along different demographical lines.

Though research behind preventive measures is lacking, there are common steps that could be taken to reduce pediatric risk.

As new methods of treatment come to the market, allergists need to ensure their patients are fully informed and able to set their own goals for care.

How can physicians train parents to trust immunotherapy—an allergen exposure they were previously told to avoid?

A growing patient population and burdens of physician shortage require specialists and primary care collaborate more and more.

Assessing a food allergy patient's overall diet during immunotherapy trials could unlock understanding how the microbiome affects the allergic reaction.